Table 3.
Antibiotics | 2017 (N = 25.119) | 2018 (N = 25.449) | 2019 (N = 29.516) | 2020 (N = 30.687) | ||||
---|---|---|---|---|---|---|---|---|
n | R% | n | R% | n | R% | n | R% | |
Ampicillin/sulbactam | 17.398 | 29.6 | 22.858 | 29.0 | 26.720 | 30.0 | 28.241 | 29.7 |
Cefoperazone/sulbactam | 3.489 | 7.0 | 6.123 | 12.4 | 9.117 | 12.0 | 13.322 | 11.2 |
Piperacillin/tazobactam | 24.462 | 8.5 | 24.796 | 8.4 | 28.166 | 9.0 | 30.444 | 9.3 |
Cefazolin | 7.335 | 37.8 | 11.069 | 33.8 | 15.032 | 33.2 | 16.480 | 33.8 |
Cefuroxime | 8.898 | 29.7 | 10.299 | 31.3 | 16.431 | 30.1 | 18.340 | 28.1 |
Ceftazidime | 22.899 | 16.8 | 23.890 | 16.5 | 29.082 | 16.6 | 30.167 | 16.4 |
Ceftriaxone | 18.682 | 29.9 | 23.371 | 27.2 | 27.858 | 26.5 | 30.348 | 25.1 |
Cefotaxime | 4.612 | 27.1 | 4.067 | 26.7 | 5.251 | 25.9 | 9.404 | 27.1 |
Cefepime | 20.309 | 13.8 | 20.958 | 13.8 | 26.162 | 13.3 | 28.773 | 13.5 |
Cefoxitin | 7.648 | 14.2 | 8.182 | 16.1 | 8.657 | 16.5 | 8.447 | 13.5 |
Ertapenem | 13.678 | 2.1 | 16.172 | 4.3 | – | – | 23.115 | 3.8 |
Imipenem | 24.239 | 4.8 | 24.984 | 6.2 | 28.909 | 6.7 | 30.083 | 6.5 |
Meropenem | 10.365 | 5.7 | 11.570 | 7.3 | 14.014 | 8.0 | 15.162 | 7.5 |
Amikacin | 24.697 | 2.5 | 24.630 | 4.6 | 28.988 | 4.1 | 30.100 | 5.0 |
Gentamicin | 24.809 | 15.7 | 25.391 | 14.9 | 29.219 | 14.7 | 28.730 | 14.6 |
Ciprofloxacin | 23.735 | 14.7 | 24.801 | 15.4 | 28.782 | 15.5 | 24.150 | 26.5 |
Trimethoprim-sulfamethoxazole | 23.996 | 25.4 | 23.969 | 24.2 | 28.519 | 24.1 | 29.689 | 23.8 |
Tigecycline | 3.015 | 2.4 | 5.652 | 0.4 | 8.412 | 0.7 | 10.597 | 0.6 |
N, the annual total number of K. pneumoniae; n, the actual number of each antibiotics testing susceptibility, R%, the resistance rates of K. pneumoniae to each antibiotic; -, not available.